


## Acquisition Brief — xgenetics.ai



## Acquisition Brief — Xgenetics.ai

**Domain name / Asset offered:** xgenetics.ai (single asset; no other extensions included)

**Purpose:** acquisition of a strategic digital banner to host and steer an AI-enabled genetics programme (R&D, data, safety/ethics, clinical & industrial partnerships).

### Contacts

**Email** • [contact@xgenetics.ai](mailto:contact@xgenetics.ai)

**Website** • <https://www.xgenetics.ai>

**LinkedIn** • <https://www.linkedin.com/company/xgeneticsai>

---

### This document — for whom, and why

**Decision brief for CEO / COO / CFO / CTO / Chief Medical Officer / Regulatory & Ethics**

(digital health, rare diseases, biotech, pharma, hospitals, data platforms).

**Thesis:** owning the language of the category creates operational and reputational advantage.

**XGENETICS.AI** is a neutral banner to align R&D, Data, Clinical, Quality/Regulatory, Safety & Ethics around:

- rare genetic diseases,
  - undiagnosed conditions (“X diseases”, SWAN),
  - AI programmes applied to human genetics.
-

## **1. One-page decision**

**What it is.**

**A strategic (.ai) asset to name, structure and make visible a “Genetics & AI” programme:**

- institutional public portal,
- internal framework (data / model governance),
- anchor point for the ecosystem (patients, clinicians, partners, investors).

**What it changes.**

- Single entry point → clear narrative for patients, authorities, partners.
- Readable programme → better coordination between R&D, IT/Data, clinical, legal, ethics.
- Reduced time-to-trust → the programme brand becomes a reference in an anxiety-prone area (AI + genetics).

**What you can deploy immediately.**

- “Genetics & AI — Readiness & Rollout” programme: vision, priority use cases, roadmap.
- Resource hub: best practices (data quality, model robustness, explainability).
- Ethics & communication framework: validated messages for patients, regulators, media, investors.

---

## **2) Market context & 2025-2032 window**

- Acceleration of large-scale sequencing and analysis.
- Growing use of AI for variant interpretation and patient stratification.
- Increasing regulatory pressure: data protection, algorithm transparency, informed consent.
- Strong societal expectations around rare diseases and undiagnosed conditions.

**In this context, a genetics & AI programme that is poorly named or fragmented becomes:**

- harder to explain,
- more exposed in the media,
- riskier with authorities and ethics committees.

**XGENETICS.AI** offers a durable programme banner for this new generation of initiatives.

---

### **3) The problem to solve (Board view)**

**Without a clear banner:**

- Multiple internal “AI projects” with no overall coherence.
- Difficulty telling a simple story to patients, clinicians, payers, investors.
- Communication risk: AI + genetics is sensitive; misunderstandings are costly.
- Fragmented data & model governance → higher risk on confidentiality, bias, compliance.

**Board-level question:**

**“How do we make this programme readable, governable and defensible in front of patients, authorities and the media for the next 10 years?”**

---

### **4) What XGENETICS.AI enables**

#### **4.1. Neutral, extensible programme name**

- Suitable for a foundation, hospital, private group, biopharma, data platform.
- Can cover research, clinical pilots, and patient-facing digital services.
- Does not compete with existing brands: it sits above them as a programme banner.

#### **4.2. Data & AI governance framework**

- Public page: principles, charters, committees, transparency reports.
- Internal layer: shared reference for collecting, storing, accessing and using sensitive data.

#### **4.3. Strong signal to the ecosystem**

- Clear message to expert centres, patient organisations, industrial partners: “We run a structured AI & genetics programme and here is where to find it.”

#### **4.4. Reputational & ESG asset**

- **Traceability of commitments (reports, indicators, publications).**
  - **Better readability for investors, analysts and regulators on risk and impact management.**
- 

#### **5) Priority use cases (12–36 months)**

##### **Examples:**

- **Hospital / hospital network: central programme for rare diseases & SWAN patients.**
  - **Biopharma / biotech: banner for a portfolio of clinical trials where AI interacts with genetic data.**
  - **Digital health platform: trust hub explaining how AI is used on very sensitive data.**
  - **National / regional initiative: framework to coordinate several centres or patient registries.**
- 

#### **6) Governance & internal integration**

##### **Possible options:**

- **Domain hosted at corporate level (Communications / Corporate Affairs).**
  - **Joint ownership by Medical leadership & Data/AI leadership, with a dedicated ethics committee.**
  - **Governance documented on xgenetics.ai:**
    - **committee composition,**
    - **rules for selecting use cases,**
    - **principles for model updates and withdrawals.**
-

## **7) Integration with existing brands & products**

- **XGENETICS.AI is not a product brand, but a programme umbrella.**
  - **Product, trial, platform or app names remain unchanged; they cascade under the banner.**
  - **Controlled co-branding: “XGENETICS.AI programme — [Study / platform name]”.**
  - **Reduced risk of proliferating slogans or brands that are hard to maintain over time.**
- 

## **8) Scope of transfer & options**

- **Asset transferred: xgenetics.ai only.**
  - **“Bare” domain transfer: no transfer of data, software, or intellectual property on models/algorithms.**
  - **Option to discuss, at buyer’s request, the addition of one extra digital asset to reinforce the programme (to be defined during negotiation).**
  - **No other name is mentioned in this document; at most one additional asset could be considered, outside the scope of this brief.**
- 

## **9) Acquisition process (Legal/Finance)**

- **Object of transfer: xgenetics.ai only.**
- **Standard process:**
  - **agreement on price and terms,**
  - **domain transfer agreement,**
  - **optional escrow service,**
  - **fast domain transfer,**
  - **invoice issued (French / European structure).**

- **Possible structures:**
  - lump-sum payment,
  - staged payment (e.g. 40-30-30, to be discussed),
  - potential bundle with other digital assets, if relevant for the buyer.
- **NDA and limited audit (targeted due diligence on the asset) available if needed.**

**Legal notice:**

- **Descriptive name, no affiliation with any existing entity;**
- **No medical claims: the name does not replace regulatory approvals, clinical validation or marketing authorisations.**

---

**10) Contacts**

**Email • [contact@xgenetics.ai](mailto:contact@xgenetics.ai)**

**Website • <https://www.xgenetics.ai>**

**LinkedIn • <https://www.linkedin.com/company/xgeneticsai>**